The Invention Science Fund I LLC

Institute for Systems Biology

California Institute of Technology

University of Washington

Other

Cornell Research Foundation Inc.

Fred Hutchinson Cancer Center

Stowers Institute for Medical Research

The University of Chicago

Searete LLC

University of Strathclyde

University of Leeds

University of Sheffield

Université Libre De Bruxelles

Gearbox LLC

Leroy E Hood

Lowell L Wood, Jr

Clarence T Tegreene

Edward K Y Jung

Muriel Y Ishikawa

Robert Samuel Langer

Victoria Y H Wood

Michael W Hunkapiller

Biaoyang Lin

Lloyd M Smith

Lawrence A Loeb

Andrew F Siegel

Motoshi Suzuki

Elizabeth A Sweeney

Francis Barany

Charles R Connell

William J Dreyer

Linheng Li

Zhen Guo

Robert J Kaiser, Jr

Anton W Stark

John Zebala

Deborah Nickerson

Tim J Hunkapiller

Qiang Tian

Effie W Petersdorf

Rodney M Hewick

Yong Zhou

Kai Hua Wang

Weiguo Andy Tao

Rima McLeod

Kamal El Bissati

Craig Roberts

Xi C He

Preet M Chaudhary

Tong Yin

Mark Hickman

QiGui Li

Taek-Kyun Kim

Martin McPhillie

Inyoul Lee

Hernan Alejandro Lorenzi

Colin W G Fishwick

Irving L Weissman

Stanley B Prusiner

Eleanor V Goodall

Richard L Moore

Marcello Marelli

Timothy Hunkapiller

Ying Zhou

David Westaway

Decio L Eizirik

Marie-Claire Beckers

Daisy Flamez

Michael S McGrath

Patricia M Beckmann

Daniel Maréchal

Ulf Landegren

Greg D Foltz

Kai Wang

Richard Johnson

Xiaowei Yan

Zhiyuan Hu

Christopher Lausted

Xiaojun Li

Isabelle Salmon

Alix Berton

Isabelle Roland

Nathan Goodman

Burak Kutlu

Robert J Kaiser

Trey E Ideker

Ji Hoon Cho

Dhimankrishna Ghosh

Nancy B Spinner

Ian D Krantz

Patrick Tremblay

Deborah A Nickerson

Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases

Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

Concentrations of certain miRNA, mRNA and/or protein markers in the biological fluids and/or tissues of a subject are used to determine the probability that the subject does or does not have Posttraumatic Stress Disorder (PTSD). The concentrations of these markers in fluids and/or tissues are different in subjects with PTSD as compared to subjects who do not suffer from this disorder.

Markers and methods for detecting posttraumatic stress disorder (PTSD)

Embodiments of a system including a remotely controlled reaction device and associated controller are described. Methods of use and control of the device are also disclosed. According to various embodiments, a reaction device is placed in an environment in order to perform a chemical reaction in an environment. Exemplary environments include a body of an organism, a body of water, or an enclosed volume of a fluid. In selected embodiments, a magnetic field, an electric field, or electromagnetic control signal may be used.

In situ reaction device

The present invention relates to a purified molecules, including antibodies, that bind specifically to murine &#x3b2;-catenin phosphorylated at amino acid position Serineand to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.

Method of detecting phosphorylation state of beta-catenin

Remote controlled in vivo reaction method

The present invention relates generally to methods for identifying organ-specific secreted proteins and for identifying organ-specific molecular blood fingerprints therefrom. As such, the present invention provides compositions comprising such proteins, detection reagents for detecting such proteins, and panels, and arrays for determining organ-specific molecular blood fingerprints.

Methods for identifying and using organ-specific proteins in blood

The present invention relates generally to methods for identifying drug side effects by detecting perturbations in organ-specific molecular blood fingerprints. The invention further relates to methods for identifying drug-specific organ-specific molecular blood fingerprints. As such, the present invention provides compositions comprising organ-specific proteins, detection reagents for detecting such proteins, and panels and arrays for determining organ-specific molecular blood fingerprints.

Methods for identifying and monitoring drug side effects

Embodiments of a system including a remotely controlled osmotic pump device and associated controller are described. Methods of use and control of the device are also disclosed. According to some embodiments, an osmotic pump device is placed in an environment in order to pump a material into the environment or into an additional fluid handling structure within the osmotic pump device. Exemplary environments include a body of an organism, a body of water, or an enclosed volume of a fluid. In selected embodiments, a magnetic field, an electric field, or electromagnetic control signal may be used.

Osmotic pump with remotely controlled osmotic pressure generation

Methods and systems described herein include individual-use beverage containers including sensors and methods of their use. Beverage containers include: a vessel body configured to hold a beverage; and at least one sensor associated with the vessel body, the at least one sensor including a sensor configured to detect one or more substance in a fluid. Systems include: at least one beverage container including at least one sensor configured to detect one or more substance in fluid; and at least one external device including at least one port configured for communication with the at least one sensor. Methods include: detecting one or more substance within fluid with at least one sensor integral to a beverage container; and interfacing one or more of the at least one sensor with an external device.

Beverage containers with detection capability

Remote control of osmotic pump device

Remote controlled in situ reaction method

Embodiments of a system including a remotely controlled substance delivery device and associated controller are described. Methods of use and control of the device are also disclosed. According to some embodiments, a delivery device or related device may be placed in an environment in order to pump a material into the environment or into an additional fluid handling structure within the device. Exemplary environments include a body of an organism, a body of water, or an enclosed volume of a fluid. The concentration of a substance in the fluid to be delivered may be modified by a remote control signal. In selected embodiments, an acoustic control signal may be used.

Acoustically controlled substance delivery device

Growing community of inventors

Seattle, WA, United States of America

Leroy E Hood